Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) Share Price

Company Profile

Business description
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Contact
No. 699, Maliu Avenue
Area A, Building 2
International Bio City
Banan
Chongqing401338
CHN
T: +86 2361758666
http://www.genrixbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
743

Recommended

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.

Angus Hewitt, CFA | 30 July 2025

Our latest articles about where we see opportunities in the market.

Morningstar | 28 July 2025

Banking Analyst Nathan Zaia’s analysis of MQG’s results.

Nathan Zaia | 28 July 2025

Index	Last price	Change	% Change
All Ordinaries	9,023.30	56.60	0.63%
CAC 40	7,857.36	56.48	0.72%
DAX 40	24,217.37	247.01	1.03%
Dow JONES (US)	44,632.99	204.57	-0.46%
FTSE 100	9,136.32	54.88	0.60%
HKSE	25,473.40	51.05	-0.20%
NASDAQ	21,098.29	80.29	-0.38%
Nikkei 225	40,682.14	7.59	0.02%
NZX 50 Index	12,961.28	24.87	0.19%
S&P 500	6,370.86	18.91	-0.30%
S&P/ASX 200	8,764.10	59.50	0.68%
SSE Composite Index	3,632.41	22.70	0.63%